Skip to main content
Caplight Logo









Rivus Pharmaceuticals

Rivus Pharmaceuticals

Private
Charlottesville, VirginiaHealthcare & Life Scienceshttps://www.rivuspharma.com/

Last Round

Series B

Sep 22, 2022

Total Funding Raised

$167M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Rivus Pharmaceuticals is a biopharmaceutical company that develops controlled metabolic accelerators aimed at enhancing cardio-metabolic health through oral small-molecule therapeutics targeting the root causes of metabolic and cardiovascular diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologymetabolic therapycontrolled metabolic acceleratorCMAMASHmetabolic dysfunction-associated steatohepatitisGLP-1 receptor agonistGLP-1obesity treatmentweight loss drugclinical trialdrug discoverycardiometabolic diseasesmall molecule therapeuticsmitochondrial biologybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rivus Pharmaceuticals Comparables

Compare Rivus Pharmaceuticals with similar companies based on industry and business-model similarity.

Rivus Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OrsoBio
85%
Roche Holding
82%
Terns Pharmaceutical
81%

Rivus Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 22, 2022
Series AJul 20, 2021

Key People

Founding team and executive leadership

Allen Cunningham

Chief Executive Officer

Executive Team

Rivus Pharmaceuticals Investors

Notable investors and investment history

Rivus Pharmaceuticals investors
InvestorRounds
Longitude CapitalSeries B, Series A
Bain Capital Life SciencesSeries B
RA Capital ManagementSeries B
BB BiotechSeries B
MedicxiSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors increased 114% MoM.

  • Feb 27, 2026

    Allen Cunningham transitions to Chief Operating Officer.

Rivus Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rivus Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rivus Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersCharlottesville, Virginia
Employee Range29
Year Founded2019
Last FundingSep 22, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?